Humacyte, Inc. (HUMA) vs Voyager Therapeutics, Inc. (VYGR)

Humacyte, Inc. and Voyager Therapeutics, Inc. are both Biotechnology companies. Humacyte, Inc. and Voyager Therapeutics, Inc. are of similar size ($172.5M and $166.7M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against −19.1%. Voyager Therapeutics, Inc. has the higher net margin (−312.6% vs −4,448.9%) and the higher return on invested capital (−192.6% vs −433.7%). Across the 17 metrics below, Voyager Therapeutics, Inc. leads on 13 and Humacyte, Inc. on 4.

Valuation

Metric HUMA VYGR Biotechnology median
P/E n/m n/m 7.88
P/S 61.83 4.71 11.47
P/B 4.20 1.05 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 55.84 1.33 10.73
Earnings yield (87.50%) (67.54%) (28.84%)
Free cash flow yield (74.39%) (74.83%) (23.03%)

Profitability

Metric HUMA VYGR Biotechnology median
Gross margin (494.58%) 100.00% 65.16%
Operating margin (5,240.78%) (340.08%) 0.00%
Net margin (4,448.89%) (312.63%) 0.00%
Free cash flow margin (4,599.72%) (352.36%) 0.00%
Return on equity (534.42%) (54.09%) (57.72%)
Return on assets (68.16%) (41.45%) (49.22%)
Return on invested capital (433.66%) (192.55%) 0.00%

Growth

Metric HUMA VYGR Biotechnology median
Revenue growth (TTM) 149.82% (19.07%) 5.64%
EPS growth (last fiscal year) 79.37% (80.53%) —
Revenue growth, 5-year CAGR — (25.09%) 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HUMA VYGR Biotechnology median
Debt to equity 2.07 0.00 0.00
Current ratio 6.21 7.51 4.73
Net debt to EBITDA (0.12) 1.50 0.96

Dividend

Metric HUMA VYGR Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HUMA VYGR Biotechnology median
Market cap 166.65m 172.53m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack